新乡市常乐制药有限责任公司

Xinxiang Changle Pharmaceutical Co., Ltd. is a comprehensive pharmaceutical manufacturing company based in Huixian City, Henan Province, China. Established in 2002, the company specializes in the development, production, and marketing of generic chemical drug formulations across four main dosage forms: small-volume injections, tablets, capsules, and granules. Its extensive product portfolio includes essential medicines such as estazolam tablets for anxiety and insomnia, metoclopramide hydrochloride injections for gastrointestinal disorders, and atropine sulfate injections. The company operates advanced manufacturing facilities that comply with national Good Manufacturing Practice (GMP) standards, enabling large-scale production for both domestic and international markets. In January 2025, the company was acquired by Jiangsu Lianhuan Pharmaceutical Co., Ltd., becoming its controlled subsidiary and integrating into its broader pharmaceutical network.